ATHE
Price
$4.05
Change
-$0.06 (-1.46%)
Updated
Sep 11 closing price
Capitalization
72.57M
Intraday BUY SELL Signals
SLDB
Price
$8.70
Change
-$0.37 (-4.08%)
Updated
Sep 11 closing price
Capitalization
932.32M
60 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ATHE vs SLDB

ATHE vs SLDB Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ATHE vs. SLDB commentary
Sep 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATHE is a Hold and SLDB is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SLDB($932M) has a higher market cap than ATHE($72.6M). SLDB YTD gains are higher at: 54.255 vs. ATHE (31.494). ATHE has higher annual earnings (EBITDA): -24.98M vs. SLDB (-210.48M). SLDB has more cash in the bank: 378M vs. ATHE (37.3M). ATHE has less debt than SLDB: ATHE (193K) vs SLDB (20.2M). ATHE (0) and SLDB (0) have equivalent revenues.
ATHESLDBATHE / SLDB
Capitalization72.6M932M8%
EBITDA-24.98M-210.48M12%
Gain YTD31.49454.25558%
P/E RatioN/AN/A-
Revenue00-
Total Cash37.3M378M10%
Total Debt193K20.2M1%
FUNDAMENTALS RATINGS
ATHE vs SLDB: Fundamental Ratings
ATHE
SLDB
OUTLOOK RATING
1..100
6779
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
26
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
6038
P/E GROWTH RATING
1..100
1003
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SLDB's Valuation (26) in the Biotechnology industry is somewhat better than the same rating for ATHE (79). This means that SLDB’s stock grew somewhat faster than ATHE’s over the last 12 months.

SLDB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ATHE (100). This means that SLDB’s stock grew similarly to ATHE’s over the last 12 months.

SLDB's SMR Rating (98) in the Biotechnology industry is in the same range as ATHE (98). This means that SLDB’s stock grew similarly to ATHE’s over the last 12 months.

SLDB's Price Growth Rating (38) in the Biotechnology industry is in the same range as ATHE (60). This means that SLDB’s stock grew similarly to ATHE’s over the last 12 months.

SLDB's P/E Growth Rating (3) in the Biotechnology industry is significantly better than the same rating for ATHE (100). This means that SLDB’s stock grew significantly faster than ATHE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATHESLDB
RSI
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
80%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
75%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
86%
Advances
ODDS (%)
N/A
Bullish Trend 10 days ago
80%
Declines
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
89%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
72%
Aroon
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
87%
COMPARISON
Comparison
Sep 12, 2026
Stock price -- (ATHE: $4.05 vs. SLDB: $8.70)
Brand notoriety: ATHE and SLDB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATHE: 170% vs. SLDB: 133%
Market capitalization -- ATHE: $72.57M vs. SLDB: $932.32M
ATHE [@Biotechnology] is valued at $72.57M. SLDB’s [@Biotechnology] market capitalization is $932.32M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.64B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATHE’s FA Score shows that 0 FA rating(s) are green while SLDB’s FA Score has 2 green FA rating(s).

  • ATHE’s FA Score: 0 green, 5 red.
  • SLDB’s FA Score: 2 green, 3 red.
According to our system of comparison, SLDB is a better buy in the long-term than ATHE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATHE’s TA Score shows that 4 TA indicator(s) are bullish while SLDB’s TA Score has 5 bullish TA indicator(s).

  • ATHE’s TA Score: 4 bullish, 4 bearish.
  • SLDB’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both ATHE and SLDB are a good buy in the short-term.

Price Growth

ATHE (@Biotechnology) experienced а -10.79% price change this week, while SLDB (@Biotechnology) price change was -15.12% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.09%. For the same industry, the average monthly price growth was -3.45%, and the average quarterly price growth was +2531.70%.

Reported Earning Dates

SLDB is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-6.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ATHE
Daily Signal:
Gain/Loss:
SLDB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ALTEX13.15N/A
N/A
Firsthand Alternative Energy
BREBX10.21N/A
N/A
iShares FTSE NAREIT All Eq REIT Idx
FICEX15.08N/A
N/A
Frost Growth Equity Inst
LLGLX13.88N/A
N/A
Longleaf Partners Global
HGOVX87.55N/A
N/A
Hartford Growth Opportunities R6